The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis

Krutikov, Maria; Faust, Lena; Nikolayevskyy, Vladyslav; Hamada, Yohhei; Rk, Gupta; Cirillo, Daniela María; Mateelli, A; Korobitsyn, Alexei; Denkinger, Claudia M.; Rangaka, Molebogeng X

doi:10.1016/s1473-3099(21)00261-9

Cited by 42 publications

(35 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to a meta-analysis, DST showed 86% sensitivity regardless of age and the accuracy is 95.1%. More importantly, DST showed its highest sensitivity (100%) among children and 60% sensitivity among HIV-positive patients [56]. The most recent systematic review and a metaanalysis among sub-populations of adults and children with HIV, children, individuals diagnosed with TB, and those exposed to the disease for all four tests; Diaskintest, C-Tb skin test, EC-skin test, and DPPD test, had a similar agreement with IGRA and TST (80% and more).…”

Section: Tuberculin Skin Testsmentioning

confidence: 97%

“…In recent years, conventional TST was modified into four newer simple skin-based test strategies: Diaskintest (Generium Pharmaceutical, Moscow, Russia), C-Tb skin test (Statens Serum Institut, Copenhagen, Denmark), EC-skin test (Zhifei Longcom Biologic Pharmacy Co., Anhui, China) [55] and the DPPD test (Host Directed Therapeutics Bio Corp, Seattle, WA, USA). All these tests utilize recombinant ESAT-6 (dimer) and CFP-10 (monomer) antigens derived from M. tuberculosis and modified to obtain better specificity, sensitivity, and accuracy, except in the DPPD test which is a recombinant protein based on amino acids from the N-terminus sequence [56].…”

Section: Tuberculin Skin Testsmentioning

confidence: 99%

“…Overall, with the available data, all novel skin tests show similar diagnostic performance with IGRA and TST proving the possibility to replace the expensive skin tests with simpler skin-test platforms. However, more studies are demanded on both the EC-skin test and DPPD test [56].…”

Section: Tuberculin Skin Testsmentioning

confidence: 99%

See 2 more Smart Citations

Tuberculosis Diagnosis in the Era of SARS-CoV-2

Bandara

Magana-Arachchi

2022

SAJRM

View full text Add to dashboard Cite

Tuberculosis (TB) continues to be a global public health emergency responsible for approximately 1.3 million deaths annually. Enduring the existing TB challenges, the emergence of “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2), a similar respiratory infection threatened the success of TB control over the past few years. Contemplating the irreversible damage of the human immunodeficiency virus (HIV), one of the leading immune-suppressive conditions, a similar or worst expected with this synergism: TB-HIV-SARS-CoV-2. Therefore, an integrated approach is much demanded before the impending revolution, "Next Global Pandemic". The advancement of molecular diagnostic techniques, blood transcriptomics uncovered the importance of studying the cross-talk between host and pathogens. RNA-sequencing is a high-throughput sequencing technique allowing detailed characterization of gene expression profiles. With the impact of SARS-CoV-2 on host immunity, pathogen-derived biomarker identification is more disease-specific and constrains individual variations faced during host biomarker identification. However, several technical hurdles are encountered during the study of intracellular pathogens like Mycobacterium tuberculosis. The development of advanced RNA-sequencing techniques to tackle the issues targeting the host and pathogen interactions is in their infancy and restricted to in-vitro studies. Few studies on serum exosomal RNA-sequencing of active and latent TB patients enlightened the path of TB biomarker discovery urging the necessity of more studies. Thus, this review will explicitly discuss the existing TB diagnostic tools to understand where we stand in TB diagnosis and the recent advancements in blood transcriptomics emphasizing the importance of targeting the pathogen-derived biomarkers as a potential source for future diagnostics.

show abstract

Section: Tuberculin Skin Testsmentioning

confidence: 97%

Section: Tuberculin Skin Testsmentioning

confidence: 99%

See 1 more Smart Citation

Tuberculosis Diagnosis in the Era of SARS-CoV-2

Bandara

Magana-Arachchi

2022

SAJRM

View full text Add to dashboard Cite

show abstract

“…and C-TST, recommended for use by WHO in 2022 [48]; these use the same M. tuberculosisspecific antigens (such as ESAT6 and CFP10) as IGRAs, but in the skin test formulation which avoids the need for laboratory processing [49][50][51]. Secondly, novel IGRA assays reduce the need for laboratory processing by using alternatives to enzyme-linked immunosorbent assays to measure interferon-gamma production (e.g.…”

Section: Diagnostic Limitations and Advancesmentioning

confidence: 99%

“…The lack of a gold-standard test for Mtb infection makes it challenging to assess the performance of novel diagnostics. Specific skin tests (such as C-Tb, Diaskintest and C-TST) have sensitivities of 75-91% in people with TB disease, high specificity amongst those at low risk of TB, and an agreement of 80-87% with IGRA [48,51]. Newer IGRA platforms, such as the QIAreach-QFT, appear promising but have not been evaluated in population-based studies [53].…”

Section: Which Diagnostic Tests Should Be Used and How?mentioning

confidence: 99%

Know your tuberculosis epidemic–Is it time to add Mycobacterium tuberculosis immunoreactivity back into global surveillance?

Rickman

Kamchedzera²,

Schwalb³

et al. 2022

PLOS Glob Public Health

View full text Add to dashboard Cite

Tuberculosis (TB) still causes 1.5 million deaths globally each year. Over recent decades, slow and uneven declines in TB incidence have resulted in a falling prevalence of TB disease, which increasingly concentrates in vulnerable populations. Falling prevalence, while welcome, poses new challenges for TB surveillance. Cross-sectional disease surveys require very large sample sizes to accurately estimate disease burden, and even more participants to detect trends over time or identify high-risk areas or populations, making them prohibitively resource-intensive. In the past, tuberculin skin surveys measuring Mycobacterium tuberculosis (Mtb) immunoreactivity were widely used to monitor TB epidemiology in high-incidence settings, but were limited by challenges with both delivering and interpreting the test. Here we argue that the shifting epidemiology of tuberculosis, and the development of new tests for Mtb infection, make it timely and important to revisit the strategy of TB surveillance based on infection or immunoreactivity. Mtb infection surveys carry their own operational challenges and fundamental questions, for example: around survey design and frequency; which groups should be included; how the prevalence of immunoreactivity in a population should be used to estimate force of infection; how individual results should be interpreted and managed; and how surveillance can be delivered efficiently and ethically. However, if these knowledge gaps are addressed, the relative feasibility and lower costs of Mtb infection surveillance offer a powerful and affordable opportunity to better “know your TB epidemic”, understand trends, identify high-risk and underserved communities, and tailor public health responses to dynamic epidemiology.

show abstract

Accurately Detecting Trace‐Level Infectious Agents by an Electro‐Enhanced Graphene Transistor

Dai

Yang

Xiong

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

For epidemic prevention and control, molecular diagnostic techniques such as field-effect transistor (FET) biosensors is developed for rapid screening of infectious agents, including Mycobacterium tuberculosis, SARS-CoV-2, rhinovirus, and others. They obtain results within a few minutes but exhibit diminished sensitivity (<75%) in unprocessed biological samples due to insufficient recognition of low-abundance analytes. Here, an electro-enhanced strategy is developed for the precise detection of trace-level infectious agents by liquid-gate graphene field-effect transistors (LG-GFETs). The applied gate bias preconcentrates analytes electrostatically at the sensing interface, contributing to a 10-fold signal enhancement and a limit of detection down to 5 × 10 −16 g mL −1 MPT64 protein in serum. Of 402 participants, sensitivity in tuberculosis, COVID-19 and human rhinovirus assays reached 97.3% (181 of 186), and specificity is 98.6% (213 of 216) with a response time of <60 s. This study solves a long-standing dilemma that response speed and result accuracy of molecular diagnostics undergo trade-offs in unprocessed biological samples, holding unique promise in high-quality and population-wide screening of infectious diseases.

show abstract

The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis

Cited by 42 publications

References 45 publications

Tuberculosis Diagnosis in the Era of SARS-CoV-2

Tuberculosis Diagnosis in the Era of SARS-CoV-2

Know your tuberculosis epidemic–Is it time to add Mycobacterium tuberculosis immunoreactivity back into global surveillance?

Accurately Detecting Trace‐Level Infectious Agents by an Electro‐Enhanced Graphene Transistor

Contact Info

Product

Resources

About